Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05172271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 171 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Jul 31, 2027 to Dec 4, 2025v171
  2. 3 versions Re-verified since May 29, 2026, no change to tracked fieldsv168-v170
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 35 to confirmed 8
    • Site details revised
    v167
  4. Primary completion date: Oct 31, 2025 to Jul 31, 2027
    • Study completion date: Oct 31, 2025 to Oct 31, 2027
    v166
  5. Primary completion date: Jul 31, 2025 to Oct 31, 2025v165
Show 43 earlier versionsHide 43 earlier versions
  1. 2 versions Re-verified since Jul 8, 2025, no change to tracked fieldsv163-v164
  2. Publications: 4 to 3v162
  3. 5 versions Re-verified since Mar 6, 2025, no change to tracked fieldsv157-v161
  4. Eligibility criteria expanded, about 18 words
    • Publications: 3 to 4
    v156
  5. Interventions: ECT device without stimulation (Other), MagPro TMS Stimulator and coil (Device), Magnetic Resonance Imaging Scanner (Device), Thymatron… to ECT device without stimulation (Other), MagPro TMS Stimulator and coil (Device), Magnetic Resonance Imaging Scanner (Device), Thymatron(R)…
    • Study title revised
    v155
  6. 7 versions Re-verified since Nov 23, 2023, no change to tracked fieldsv148-v154
  7. Study description revisedv147
  8. 5 versions Re-verified since Jan 24, 2023, no change to tracked fieldsv142-v146
  9. Primary completion date: Jul 23, 2025 to Jul 31, 2025
    • Study completion date: Jul 23, 2025 to Oct 31, 2025
    • Start date changed from estimate of Oct 6, 2022 to Nov 8, 2022
    v141
  10. Start date: Oct 5, 2022 to Oct 6, 2022v140
  11. Start date: Oct 4, 2022 to Oct 5, 2022v139
  12. Start date: Oct 3, 2022 to Oct 4, 2022v138
  13. Start date: Oct 2, 2022 to Oct 3, 2022v137
  14. Start date: Sep 29, 2022 to Oct 2, 2022v136
  15. Start date: Sep 28, 2022 to Sep 29, 2022v135
  16. Start date: Sep 27, 2022 to Sep 28, 2022v134
  17. Start date: Sep 26, 2022 to Sep 27, 2022v133
  18. Start date: Sep 22, 2022 to Sep 26, 2022v132
  19. Start date: Sep 21, 2022 to Sep 22, 2022v131
  20. Start date: Sep 20, 2022 to Sep 21, 2022v130
  21. Start date: Sep 19, 2022 to Sep 20, 2022v129
  22. Start date: Sep 18, 2022 to Sep 19, 2022v128
  23. Start date: Sep 15, 2022 to Sep 18, 2022v127
  24. Start date: Sep 14, 2022 to Sep 15, 2022v126
  25. Start date: Sep 13, 2022 to Sep 14, 2022v125
  26. Start date: Sep 12, 2022 to Sep 13, 2022v124
  27. Start date: Sep 8, 2022 to Sep 12, 2022v123
  28. Start date: Sep 7, 2022 to Sep 8, 2022v122
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: People with TRD are often helped by electroconvulsive therapy (ECT). But ECT can affect memory and thinking. Researchers want to study a treatment called TEST that uses less electricity. Objective: To study the safety and feasibility of TEST and assess its antidepressant effects. Eligibility: Adults aged 25-64 with major depression that has not been relieved by current treatments. Design: Participants will be admitted to the NIH Clinical Center for 5 18 weeks over 2 3 treatment phases. Their medications may be adjusted. Participants will be interviewed about their depression, side effects, and other treatments they are receiving. They will complete questionnaires. They will give blood and urine samples. Their brain waves and heart rhythm will be recorded. They will take tests of memory, attention, mental functioning, and thinking. Participants will have magnetic resonance imaging (MRI) scans of the head and brain. They will lie on a table that slides in and out of the scanner. Pictures of brain chemicals will also be taken. They may complete tasks during the MRI. Participants will receive TEST and/or sham treatments. They may receive optional ECT. An intravenous catheter will be placed in an arm vein to receive general anesthesia. Two electrodes will be placed on the front of their head. An electric current will be passed from the ECT machine through the electrodes. For sham treatments, they will not receive the electric current. Their breathing, heart rate, brain function, blood pressure, and body movements will be measured. Participants will have 7 follow-up visits over 6 months. Visits can be done via telehealth. Participation will last for up to 42 weeks.
Trial Details
NCT Number NCT05172271
Lead Sponsor National Institute of Mental Health (NIMH)
Conditions
(from sponsor)		 Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Related terms Bipolar Disorder, Major Depressive Disorder, Seizures
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov